Prof. Jacques Séguin Joins Endoron Medical as Chairman of the Board

February 1, 2023—Endoron Medical announced that Professor Jacques Séguin, MD, PhD, will join its board of directors as chairman.

Endoron is an Israel-based medical device company developing an endostapling device for the endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs). Endoron is a portfolio company of Sofinnova Partners, a European life sciences venture capital firm.

“I’m honored to be joining Endoron to support the emergence of Aortoseal in clinical practice,” commented Prof. Séguin in the company’s press release. “The technology developed by Endoron mimics the hand-sewn graft of open surgery and is on track to solve the main issue of EVAR: long-term durability. I’m convinced that Endoron is bringing a game-changing technology to the EVAR market with a very disruptive approach.”

Endoron noted that Prof. Séguin is Professor of Cardiac Surgery at Paris University in Paris, France, and holds PhDs in Biochemistry and Medical History. He has more than 20 years of experience performing more than 4,000 open heart surgeries and authoring more than 200 articles in peer-reviewed international medical journals.

Prof. Séguin founded CoreValve, Inc. and developed the company’s self-expandable transcatheter aortic valve replacement (TAVR) technology. The CoreValve TAVR system received CE Mark approval in 2007. The company was acquired by Medtronic in 2009.

He was also part of the original team at ReCor Medical, a renal denervation company that was founded by Sofinnova Partners and acquired in 2018 by Japan-based Otsuka Medical Devices Co., Ltd.

Both CoreValve and ReCor Medical were funded by Sofinnova Partners at the series A stage.

Additionally, Prof. Séguin founded Stentys and is currently the Chairman of Picardia, which are also companies backed by Sofinnova Partners.

In December 2021, Sofinnova Partners announced the placement of $5 million in seed funding for Endoron Medical to accelerate the development of the company’s endograft stapling solution for EVAR. The investment came from its medtech acceleration fund, Sofinnova MD Start III.

Ronit Harpaz, cofounder and chief executive officer of Endoron stated in the company’s press release, “We are proud and delighted to have Prof. Séguin join our board as chairman, at a pivotal time for the company. With his extensive and successful track record in the medtech field, Prof. Séguin brings to Endoron a deep knowledge and expertise to help us advance our innovative technology to the clinic. We look forward to working together to provide AAA patients undergoing EVAR with a long-lasting sealing and fixation solution for their endograft experience.”